Sciadopitysin

Research use only, not for human use.

Sciadopitysin may prevent the development of diabetic osteopathy, it exerts its therapeutic effects via upregulation of mitochondrial biogenesis.

Sciadopitysin may prevent the development of diabetic osteopathy, it exerts its therapeutic effects via upregulation of mitochondrial biogenesis.Sciadopitysin shows protective effects on antimycin A-induced toxicity in osteoblastic MC3T3-E1 cells, it may reduce or prevent osteoblasts degeneration.Sciadopitysin can inhibit the Aβ aggregation and reduce Aβ-induced toxicity in the primary cortical neurons.

Sciadopitysin (2.5, 5, 10 μM ) strongly reduces RANKL-induced osteoclast-specific genes expression, including cathepsin K (CTSK), tartrate-resistant acid phosphatase (TRAP) and MMP-9. Furthermore, Sciadopitysin apparently attenuates RANKL-increased expressions of c-Fos and NFATc1.

Sciadopitysin (i.p.; 10 mg/kg; every other day for 8 days) can reverse the bone loss in LPS-induced mice model (C57BL/6 mice; 6 weeks old).

Sciadopitysin | NSC 45108 | NSC-45108 | NSC45108

Endocrinology/Hormones

Opioid Receptor

TNF-α

Others-Field

——

521-34-6

580.54

C33H24O10

>98% (HPLC)

In Vitro:?DMSO : 20 mg/mL (34.45 mM)

Oc1cc(OC)cc2OC(=CC(=O)c12)c6cc(c5c(O)cc(O)c3c5OC(=CC3=O)c4ccc(OC)cc4)c(OC)cc6

5,7-Dihydroxy-8-(5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl)-2-(4-methoxyphenyl)-4-benzopyrone

(-20℃)

With Ice Pack

≥ 2 years